Tech Mahindra, a global leader in technology consulting and digital solutions, has partnered with NVIDIA to introduce an advanced, agentic AI-powered pharmacovigilance (PV) solution aimed at enhancing drug safety management. This collaboration leverages cutting-edge artificial intelligence to automate and optimize PV processes, addressing critical challenges such as manual delays and data overload.
Tech Mahindra’s TENO Framework and NVIDIA AI Integration
The foundation of this innovative solution is Tech Mahindra’s TENO framework, which integrates seamlessly with NVIDIA’s AI technology. By incorporating the NVIDIA AI Enterprise software platform—including NVIDIA NeMo, NVIDIA NIM microservices, and NVIDIA AI Blueprints—the solution automates various PV workflows. This integration streamlines case intake, data transformation, quality control, and compliance management, resulting in a more efficient and intelligent PV process.
Revolutionizing Drug Safety: Tech Mahindra and NVIDIA’s AI-Powered Pharmacovigilance Solution
A key feature of this solution is the use of large language model (LLM)-powered AI agents. These agents autonomously handle tasks such as case classification, prioritization, and verification of pharmacovigilance emails, significantly reducing the risk of human error. This autonomy not only enhances accuracy but also accelerates the overall PV process.
Addressing Industry Challenges
The pharmaceutical industry often contends with processing over 1,000 adverse drug reaction (ADR) cases daily for major drugs. Traditional manual processing can lead to delays and errors, potentially compromising patient safety. Revolutionizing Drug Safety: Tech Mahindra and NVIDIA’s AI-Powered Pharmacovigilance Solution addresses these challenges by instantly flagging, prioritizing, and processing ADR reports. This proactive approach ensures timely case processing, regulatory adherence, and proactive risk mitigation, transforming pharmacovigilance from a reactive to a predictive discipline.
Measurable Benefits
The implementation of this AI-powered PV solution offers several quantifiable benefits:
Reduced Turnaround Times: The solution can decrease processing times by up to 40%, ensuring that ADR cases are addressed promptly.
Enhanced Data Accuracy: By minimizing human intervention, data accuracy is improved by 30%, leading to more reliable outcomes.
Cost Reduction: Operational costs can be reduced by 25%, making the PV process more cost-effective.
These benefits collectively contribute to a more efficient and effective pharmacovigilance system, ultimately enhancing patient safety.
Leadership Perspectives
Nikhil Malhotra, Chief Innovation Officer & Global Head of AI and Emerging Technologies at Tech Mahindra, emphasized the significance of this collaboration:
“As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline the pharmacovigilance process. Together, we are revolutionizing drug safety management and using the innovative AI-driven framework to develop multiple use cases for our global customers.”
John Fanelli, Vice President of Enterprise Software at NVIDIA, also highlighted the role of AI in enhancing drug safety:
“AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively.”
Expanding AI Capabilities
Beyond pharmacovigilance, Tech Mahindra has expanded its TENO framework to encompass NVIDIA AI Enterprise, enriching it with customized AI agents to address a broad spectrum of industry challenges. The framework integrates NVIDIA NeMo to accelerate the generative AI pipeline for data collection and curation, coupled with Tech Mahindra’s VerifAI solution for data validation and governance. The distributed training and model customization capabilities embedded within the framework ensure that the AI models continuously evolve to enhance decision-making precision.
For a deeper understanding of AI-driven PV solutions, check out Pharmaceutical Technology.
Conclusion
The collaboration between Tech Mahindra and NVIDIA represents a significant advancement in drug safety management. By harnessing the power of agentic AI, this innovative pharmacovigilance solution not only improves efficiency and accuracy but also sets a new standard for proactive and predictive drug safety practices. As the pharmaceutical industry continues to evolve, such technological integrations are poised to play a pivotal role in ensuring patient safety and regulatory compliance.
#InnoglidePharma #DrugSafety #Pharmacovigilance #AIinHealthcare #TechMahindra #NVIDIA #AIforGood #HealthcareInnovation #PharmaTech #MachineLearning
